ST-2578

ST-2578 is an investigational **small-molecule** ophthalmic analgesic being developed by SiteOne Therapeutics for **ocular pain**. Available pipeline sources describe it as a **Nav1.7 blocker**, meaning it is intended to inhibit the voltage-gated sodium channel **NaV1.7** on peripheral sensory neurons and thereby reduce nociceptive signaling from the ocular surface. Publicly available information is limited, but the program appears to be positioned as a targeted, peripherally acting pain therapy for eye-related pain or ocular surface discomfort, with development reported around the **IND-enabling or IND application** stage rather than marketed use.

Other names

NaV1.7 inhibitorsNaV-1.7 inhibitorsNaV 1.7 inhibitorsNav1.7 voltage-gated sodium channel inhibitorsNav-1.7 voltage-gated sodium channel inhibitorsNav 1.7 voltage-gated sodium channel inhibitors